Top Page
Corbus Pharmaceuticals
(NASDAQ:CRBP)
Corbus Pharmaceuticals (CRBP) vs. SPDR S&P 500 ETF (SPY)
Corbus Pharmaceuticals Business Overview & Revenue Model
Corbus Pharmaceuticals Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 881.71K | 3.94M |
| Gross Profit | -15.89M | -600.00K | 0.00 | -1.49M | -757.53K | 3.94M |
| EBITDA | -68.87M | -37.74M | -40.10M | -38.73M | -54.35M | -121.12M |
| Net Income | -67.51M | -40.21M | -44.60M | -55.83M | -45.55M | -111.27M |
Balance Sheet | ||||||
| Total Assets | 109.51M | 155.88M | 28.27M | 66.31M | 107.73M | 102.29M |
| Cash, Cash Equivalents and Short-Term Investments | 26.98M | 149.06M | 20.91M | 59.20M | 97.65M | 85.43M |
| Total Debt | 2.05M | 3.24M | 20.89M | 25.09M | 26.59M | 26.84M |
| Total Liabilities | 17.37M | 13.45M | 35.18M | 33.32M | 38.62M | 57.02M |
| Stockholders Equity | 92.15M | 142.43M | -6.91M | 32.99M | 69.11M | 45.27M |
Cash Flow | ||||||
| Free Cash Flow | -59.51M | -41.79M | -36.10M | -37.56M | -48.24M | -100.17M |
| Operating Cash Flow | -59.51M | -41.79M | -36.10M | -37.54M | -48.18M | -99.69M |
| Investing Cash Flow | 64.23M | -121.31M | 35.64M | 30.07M | -73.42M | -484.49K |
| Financing Cash Flow | 2.84M | 166.58M | -2.82M | -533.62K | 60.82M | 154.87M |
Corbus Pharmaceuticals Technical Analysis
Corbus Pharmaceuticals Risk Analysis
Corbus Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $114.54M | -0.58 | -209.00% | ― | ― | 40.22% | |
49 Neutral | $144.99M | -1.48 | -55.65% | ― | ― | -17.43% | |
49 Neutral | $68.10M | -1.02 | -76.44% | ― | -10.03% | 11.06% | |
45 Neutral | $77.76M | -2.47 | -48.89% | ― | ― | -9.42% | |
42 Neutral | $103.86M | -0.97 | -85.44% | ― | ― | -505.96% |
Corbus Pharmaceuticals Corporate Events
On January 12, 2026, Corbus Pharmaceuticals updated its corporate presentation to highlight a diversified pipeline and key clinical milestones expected in 2026, underpinned by $173 million in cash, cash equivalents and investments as of November 3, 2025 and a relatively low share count of about 17.6 million common shares outstanding. The materials emphasize CRB-701 as a potentially best-in-class Nectin-4 antibody-drug conjugate with a proprietary design that delivers longer half-life, lower free MMAE exposure and a more convenient dosing regimen than current Nectin-4/MMAE competitors, alongside emerging safety data from a 167-patient dataset presented at ESMO 2025 showing lower rates of high-grade adverse events and peripheral neuropathy versus peer agents, positioning the drug to target high Nectin-4–expressing tumors such as head and neck, cervical and urothelial cancers. Corbus also outlines a 12-week, 240-patient mid-2026 obesity readout for CRB-913 and dose-escalation progress for CRB-601 in αvβ8-enriched solid tumors, signaling an active clinical year that could be pivotal for validating its oncology and metabolic franchises and strengthening its competitive standing in the ADC and obesity drug markets.
The most recent analyst rating on (CRBP) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.
On December 12, 2025, Corbus Pharmaceuticals Holdings, Inc. announced that board member Alan Holmer notified the company of his decision to retire and will resign from its Board of Directors effective December 31, 2025. The company stated that Holmer’s departure was not due to any disagreement over its operations, policies, or practices, suggesting an orderly governance transition with no underlying operational or strategic dispute signaled to stakeholders.
The most recent analyst rating on (CRBP) stock is a Buy with a $53.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.
On December 11, 2025, Corbus Pharmaceuticals announced the completion of its Phase 1a study of CRB-913, an oral CB1 inverse agonist for obesity management, and the initiation of a Phase 1b study expected to conclude in summer 2026. The Phase 1a study demonstrated that CRB-913 was safe, well-tolerated, and effective in promoting weight loss, with no serious adverse events reported, marking a significant step forward in Corbus’ obesity treatment research.
The most recent analyst rating on (CRBP) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.
Corbus Pharmaceuticals reported its third quarter 2025 financial results, highlighting significant progress in its clinical programs. The company presented promising data for CRB-701 at ESMO 2025, with plans to start a registrational study in mid-2026. Additionally, Corbus completed a $75 million public offering, extending its cash runway into 2028, and is on track to advance its CRB-913 program for obesity treatment by the end of 2025. The financial results showed an increased net loss due to higher clinical development expenses, but the company’s strong cash position supports its operations and future plans.
The most recent analyst rating on (CRBP) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.
On October 30, 2025, Corbus Pharmaceuticals announced an underwritten public offering of common stock and pre-funded warrants, aiming to raise approximately $70.5 million. The proceeds are intended to fund clinical development and general corporate purposes. The offering, managed by Jefferies and Piper Sandler, is expected to close around November 3, 2025, subject to customary conditions. This move is part of Corbus’ strategy to strengthen its financial position and advance its pipeline in the competitive oncology and obesity sectors.
The most recent analyst rating on (CRBP) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.
Corbus Pharmaceuticals Holdings, Inc. announced preliminary financial information for the quarter ended September 30, 2025, estimating cash, cash equivalents, and investments at approximately $104.0 million. This figure includes $27.0 million in cash and cash equivalents. The company emphasized that these figures are preliminary and subject to change following financial closing procedures, and stakeholders should not place undue reliance on these estimates.
The most recent analyst rating on (CRBP) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.
On October 18, 2025, Corbus Pharmaceuticals announced data from its Phase 1/2 clinical study of CRB-701, presented at the 2025 European Society for Medical Oncology Congress. The study, involving 167 patients with various tumor types, demonstrated promising efficacy and a favorable safety profile, with no dose-limiting toxicities and low discontinuation rates. The results suggest potential differentiation from other experimental agents in head and neck squamous cell carcinoma (HNSCC) and cervical cancers, highlighting a significant unmet need in these areas. Corbus plans to initiate registrational studies by mid-2026, aiming to further develop CRB-701 as a treatment option for patients with advanced solid tumors.
The most recent analyst rating on (CRBP) stock is a Buy with a $51.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.